Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05440578CT.gov First-line Olaparib Combined With Bevacizumab Maintenance Therapy | — | Unknown | — | — | — |
NCT05153603CT.gov Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting | — | Unknown | — | — | — |
NCT05252390CT.gov NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03314740CT.gov Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib | — | Completed | — | — | — |
NCT00628251CT.gov Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | — | Completed | — | — | — |
NCT00494442CT.gov Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer | — | Completed | — | — | — |
NCT00516373CT.gov A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P2 | B · 62 |
| Adriamycin | GlaxoSmithKline | P4 | BBB |
| Pazopanib | The Christie NHS Foundation Trust | P2 | BB |
| Carboplatin | Eli Lilly and Company | P3 | BB |
| Canfosfamide | Telik | P3 | BB |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | BB |
| Niraparib | GlaxoSmithKline | P4 | BB |
| Nogitecan | GlaxoSmithKline | P3 | B |
| Trabectedin | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | B |
+42 more in the Ovarian Neoplasm cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Ovarian Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-ovarian-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →